Crispr Therapeutics AG (CRSP) “Buy” Rating Kept by Analysts at Piper Jaffray; With $39.0 Target; American National Registered Investment Advisor Trimmed Microsoft (MSFT) Position

Among 6 analysts covering CRISPR Therapeutics AG – Common Shares (CRSP), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. CRISPR Therapeutics AG – Common Shares has $45 highest and $16.0 lowest target. $39.67’s average target is 13.73% above currents $34.88 stock price. CRISPR Therapeutics AG – Common Shares had 12 analyst reports since July 14, 2017 according to SRatingsIntel. On Monday, July 17 the stock rating was initiated by Oppenheimer with “Hold”. The stock of CRISPR Therapeutics AG (NASDAQ:CRSP) has “Buy” rating given on Friday, August 11 by Chardan Capital Markets. The stock of CRISPR Therapeutics AG (NASDAQ:CRSP) has “Buy” rating given on Thursday, December 21 by Piper Jaffray. The stock has “Buy” rating by SunTrust on Tuesday, January 23. The stock has “Overweight” rating by PiperJaffray on Friday, December 22. The firm has “Hold” rating by Oppenheimer given on Thursday, August 10. The firm has “Hold” rating by Oppenheimer given on Thursday, December 7. The firm earned “Hold” rating on Thursday, November 9 by SunTrust. Guggenheim maintained CRISPR Therapeutics AG (NASDAQ:CRSP) rating on Tuesday, January 9. Guggenheim has “Buy” rating and $35.0 target. The firm has “Buy” rating given on Wednesday, January 10 by Piper Jaffray.

American National Registered Investment Advisor Inc decreased Microsoft Corp (MSFT) stake by 22.5% reported in 2017Q3 SEC filing. American National Registered Investment Advisor Inc sold 17,300 shares as Microsoft Corp (MSFT)’s stock rose 4.75%. The American National Registered Investment Advisor Inc holds 59,596 shares with $4.44 million value, down from 76,896 last quarter. Microsoft Corp now has $678.97B valuation. The stock increased 3.73% or $3.17 during the last trading session, reaching $88.18. About 63.50 million shares traded or 132.19% up from the average. Microsoft Corporation (NASDAQ:MSFT) has risen 34.52% since February 10, 2017 and is uptrending. It has outperformed by 17.82% the S&P500.

Since August 29, 2017, it had 0 buys, and 2 insider sales for $5.98 million activity. 55,000 shares valued at $4.00 million were sold by Hood Amy on Tuesday, August 29. Another trade for 26,763 shares valued at $1.98 million was made by COURTOIS JEAN PHILIPPE on Wednesday, August 30.

Among 37 analysts covering Microsoft Corporation (NASDAQ:MSFT), 29 have Buy rating, 2 Sell and 6 Hold. Therefore 78% are positive. Microsoft Corporation had 166 analyst reports since July 22, 2015 according to SRatingsIntel. RBC Capital Markets maintained the stock with “Buy” rating in Monday, May 29 report. The company was initiated on Wednesday, January 11 by Wells Fargo. The stock of Microsoft Corporation (NASDAQ:MSFT) earned “Buy” rating by UBS on Friday, July 21. The company was maintained on Friday, January 29 by UBS. Jefferies maintained it with “Sell” rating and $62.0 target in Thursday, February 1 report. The stock has “Buy” rating by Oppenheimer on Wednesday, December 20. The firm has “Buy” rating given on Tuesday, October 31 by Argus Research. Canaccord Genuity maintained the shares of MSFT in report on Thursday, January 25 with “Buy” rating. The stock of Microsoft Corporation (NASDAQ:MSFT) has “Buy” rating given on Friday, January 12 by Barclays Capital. The rating was maintained by Tigress Financial on Tuesday, November 7 with “Buy”.

Investors sentiment increased to 0.83 in 2017 Q3. Its up 0.01, from 0.82 in 2017Q2. It is positive, as 40 investors sold MSFT shares while 952 reduced holdings. 114 funds opened positions while 708 raised stakes. 5.51 billion shares or 0.32% less from 5.53 billion shares in 2017Q2 were reported. Chatham Capital Grp Inc has 5,551 shares. Baldwin Invest Mgmt Limited Liability Com has 4,952 shares. Azimuth Capital Lc has invested 1.27% in Microsoft Corporation (NASDAQ:MSFT). Mckinley Carter Wealth Svcs Incorporated holds 0.35% or 12,095 shares. Lowe Brockenbrough stated it has 1.84% in Microsoft Corporation (NASDAQ:MSFT). Halbert Hargrove Russell Ltd Liability Corp holds 12,762 shares or 0.26% of its portfolio. British Columbia Investment Corporation owns 4.61M shares or 2.65% of their US portfolio. Federated Pa has 0.26% invested in Microsoft Corporation (NASDAQ:MSFT). Monetta Financial Svcs reported 2.22% stake. Credit Suisse Ag invested 1.08% of its portfolio in Microsoft Corporation (NASDAQ:MSFT). Duff & Phelps Investment Management Comm reported 86,580 shares stake. Riggs Asset Managment reported 0.12% of its portfolio in Microsoft Corporation (NASDAQ:MSFT). Churchill holds 0.05% or 26,405 shares in its portfolio. Moreover, Natl Bank Of Mellon Corp has 2.32% invested in Microsoft Corporation (NASDAQ:MSFT). Aperio Grp Incorporated Ltd holds 1.86% or 4.43M shares in its portfolio.

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 gene-editing platform in Switzerland. The company has market cap of $1.60 billion. The CRISPR/Cas9 technology allows for changes to genomic DNA. It currently has negative earnings. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies.